id.DRIVE is a Public-Private-Partnership, which consists of a unique consortium of pharmaceutical companies, public health institutes and research groups who are joining forces to monitor infectious diseases and effectiveness of related pharmaceutical products in real-life in Europe. This is achieved by several pharmaceutical companies co-funding a research network of hospitals.
id.DRIVE leverages the COVID-19 vaccine effectiveness (VE) platform, COVIDRIVE (https://covidrive.eu/) (2021-2023) and Influenza VE platform, DRIVE (https://www.drive-eu.org/) (2017-2022). The partnership decided to make use of the established consortium and study network to expend its scope to all infectious diseases (IDs), lending its name to the new partnership. Next to vaccines, other pharmaceutical products such as antivirals and monoclonal antibodies will be studied.
While id.DRIVE will continue performing COVID-19 effectiveness studies, the consortium will initiate a first surveillance study starting mid-2024 on many other respiratory pathogens such as Influenza, RSV, Adenovirus, Human enterovirus, Parainfluenza virus, etc. This surveillance will help to understand the impact of these respiratory pathogens on serious illness, and to monitor the effectiveness of pharmaceutical products which are or will be available to prevent and cure these viral illnesses.
The id.DRIVE public-private partnership includes 8 partners, with AstraZeneca, Janssen, GSK, Novavax, Valneva and Pfizer being pharmaceutical company partners, P95 a Small and Medium Enterprise and Fisabio, a Spanish regional public health institute. The id.DRIVE study network covers 13 European countries and comprises 32 Study contributors, 5 primary care networks, and a nation-wide register. id.DRIVE is open for new partners to join the partnership and is expanding its study network.
To join us as id.DRIVE partner or study site, contact us at info@idDRIVE.org.
Find out more on www.iddrive.eu